Publication | Closed Access

Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment

OncologyTherapeutic EffectBevacizumab/docetaxel AssociationMedicineImmune Checkpoint InhibitorBreast CancerPharmacotherapyAnti-cancer AgentCancer TreatmentPharmacologyCancer GrowthTumor BiologyCombined Treatment